3 ms·
Wegovy (semaglutide) and similar GLP-1 drugs are not just a one-time prescription. Most patients are likely to continue taking it forever. The trouble here is
by nradov 3y ago
Wegovy (semaglutide) and similar GLP-1 drugs are not just a one-time prescription. Most patients are likely to continue taking it forever.
The trouble here is timing and alignment of incentives. The cost of those drugs is paid by medical insurers and self-insured employers (group buyers) today. But the cost savings benefits in terms of reducing type-2 diabetes and other obesity related conditions only show up years in the future. By that time the patient will have probably moved on to another employer and another insurer (maybe Medicare). So, absent some sort of legal or regulatory mandate it's going to be difficult to convince many employers to cover such drugs.
(From a public policy standpoint it doesn't make much sense to tie medical insurance to employment, but that's another discussion.)